Subcutaneous immunoglobulin: Opportunities and outlook

Clinical and Experimental Immunology

Volumn 158, Issue SUPPL. 1, 2009, Pages 51-59

  Misbah, S ^a   Sturzenegger, M H ^b   Borte, M ^c   Shapiro, R S ^d   Wasserman, R L ^e   Berger, M ^f   Ochs, H D ^g  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d Midwest Immunology Clinic   (United States)

^e Medical City Children's Hospital   (United States)

^f CSL Behring LLC   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hyaluronidase; IgPro20; Peripheral neuropathy; Primary immunodeficiency; Subcutaneous immunoglobulin

Indexed keywords

CORTICOSTEROID; HYALURONIDASE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PEGINTERFERON;

AREA UNDER THE CURVE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL PRACTICE; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE REACTION; MOTOR NEUROPATHY; NAUSEA; PLASMAPHERESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; VOMITING; X LINKED AGAMMAGLOBULINEMIA;

ANTIGENS, NEOPLASM; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; HISTONE ACETYLTRANSFERASES; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULIN G; INFUSIONS, SUBCUTANEOUS; PERIPHERAL NERVOUS SYSTEM DISEASES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 72149122096     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04027.x     Document Type: Review

References (47)

1. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008 28 : 803 819, ix.
2. Weiler CR. Immunoglobulin therapy: history, indications, and routes of administration. Int J Dermatol. 2004 43 : 163 166.
3. Bruton OC. Agammaglobulinemia. Pediatrics 1952 9 : 722 728.
4. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007 21 : 105 116.
5. Gardulf A, Hammarström L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991 338 : 162 166.
6. Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol 2002 104 : 237 241.
7. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008 28 : 779 802, viii.
8. Chapel HM, Spickett GP, Ericson D et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000 20 : 94 100.
9. Gardulf A, Nicolay U, Asensio O et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006 26 : 177 185.
10. Ochs HD, Gupta S, Kiessling P et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006 26 : 265 273.
11. Knapp MJ, Colburn PA. Clinical uses of intravenous immune globulin. Clin Pharm 1990 9 : 909 912.
12. Ballow M, Berger M, Bonilla FA et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex (TM), 10%). Vox Sang 2003 84 : 202 210.
13. Wasserman RL, Church JA, Peter HH et al. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci 2009 37 : 272 278.
14. Gustafson R, Gardulf A, Hansen S et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 2008 152 : 274 279.
15. Waniewski J, Gardulf A, Hammarström L. Bioavailability of gammaglobulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994 14 : 90 7.
16. Gardulf A, Nicolay U, Math D et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004 114 : 936 942.
17. Nicolay U, Kiessling P, Berger M et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006 26 : 65 72.
18. Gardulf A, Andersen V, Björkander J et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995 345 : 365 369.
19. Högy B, Keinecke HO, Borte M. Pharmaco-economic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econom 2005 50 : 24 9.
20. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008 122 : 1238 1239.
21. European Medicines Evaluation Agency (EMEA). Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use. CPMP/BPWG/283/00. 2002. Available at: http://www.emea.europa.eu/pdfs/human/bpwg/ 028300en.pdf (accessed 18 May 2009).
22. European Federation of Neurologocal Societires (EFNS). EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008 15 : 893 908.
23. Bouche P, Moulonguet A, Younes-Chennoufi AB et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995 59 : 38 44.
24. Olney RK, Lewis RA, Putnam TD et al. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 2003 27 : 117 121.
25. Parry GJ, Clarke S Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 1988 11 : 103 107.
26. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 2005 31 : 663 680.
27. Van Schaik IN, Bouche P, Illa I et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 2006 13 : 802 808.
28. Van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005 2 : CD004429.
29. Azulay JP, Blin O, Pouget J et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994 44 : 429 432.
30. Federico P, Zochodne DW, Hahn AF et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000 55 : 1256 1262.
31. Leger JM, Chassande B, Musset L et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001 124 : 145 153.
32. Van den Berg LH, Kerkhoff H, Oey PL et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995 59 : 248 252.
33. Terenghi F, Cappellari A, Bersano A et al. How long is IVIg effective in multifocal motor neuropathy?. Neurology 2004 62 : 666 668.
34. Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002 125 : 1875 1886.
35. Delmont E, Azulay JP, Uzenot D et al. Long-term follow-up of multifocal motor neuropathy with conduction block under intravenous immunoglobulin. Rev Neurol 2007 163 : 82 8.
36. Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005 352 : 1343 1356.
37. Van Schaik IN, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2002 2 : CD001797.
38. Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate chromatography purified for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008 7 : 136 144.
39. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008 28 : 779 802.
40. Köller H, Schroeter M, Feischen H et al. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 2006 253 : 1505 1506.
41. Lee DH, Linker RA, Paulus W et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008 37 : 406 409.
42. Harbo T, Andersen H, Hess A et al. Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. Eur J Neurol 2009 16 : 631 638.
43. Toubi E, Etzioni A. Intravenous immunoglobulin in immunodeficiency states: state of the art. Clin Rev Allergy Immunol 2005 29 : 167 172.
44. Thomas JR, Yocum RC, Haller MF et al. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med 2007 10 : 1312 1320.
45. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Exp Opin Drug Deliv 2007 4 : 427 440.
46. Bookbinder LH, Hofer A, Haller MF et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006 114 : 230 241.
47. Olsson O, Lofgren O. Hyaluronidase as a factor hastening the spread and absorption of water-soluble radiopaque substances deposited intracutaneously, subcutaneously, or intramuscularly. Acta Radiol 1949 31 : 250 256.